As President Vladimir V. Putin of Russia declared on Tuesday that his nation had approved the world's first coronavirus vaccine without extensive clinical trials, public health experts worried that President Trump would feel the need to compete
President Donald Trump addresses a news conference at the White House in Washington, Tuesday, Aug. 11, 2020. As President Vladimir Putin of Russia declared that his nation had approved the world’s first coronavirus vaccine without extensive clinical trials, public health experts worried that President Trump would feel the need to compete
Image: Doug Mills/The New York Times
American scientists hope this is one time that President Donald Trump really does believe it is all just a Russian hoax.
As President Vladimir Putin of Russia triumphantly declared on Tuesday that his country had produced the world’s first coronavirus vaccine, public health experts in the United States worried that Trump would feel compelled to compete in a pharmaceutical manhood contest by hastily rolling out his own vaccine even before it is fully tested.
“I am sure that this will give him more impetus to push U.S. R&D and FDA to move more quickly,” Margaret Hamburg, a Food and Drug Administration commissioner under President Barack Obama, said, referring to research and development. “If he believes that testing causes cases, I suspect he may believe that if you don’t test a vaccine or drug, they must be OK.”
The announcement in Moscow roiled the international quest to stop the pandemic in what had already developed into a geopolitical race among the world’s biggest powers. The Russian vaccine, approved without the sort of extensive trials typically required in the West, may work, American scientists said. But if it does not, the rushed process could pose dangers not just for Russians but for many others if Trump seeks to match the supposed achievement prematurely.
The search for a vaccine has already been caught in a whirlwind of pressures as the Trump administration scrambles to develop a drug to combat a virus that has killed more than 164,000 Americans. Two pharmaceutical companies have moved to Phase 3 trials in the United States, the final stage of testing before a vaccine can be approved. But scientists have expressed concern that the trials would be short-circuited by Trump’s desire for a political win before the general election Nov. 3.
©2019 New York Times News Service